medigraphic.com
ISSN 1995-9427 (Print)

2020, Number 1

<< Back Next >>

Invest Medicoquir 2020; 12 (1)

Control gliycaemic and complications macro vascular in patients with diabetes mellitus type II

Ramírez RAG, Ramírez MY, Iglesias M

Language: Spanish
References: 35
Page: 1-17
PDF size: 232.48 Kb.


ABSTRACT

Introduction. Impaired control of glucose causes the onset of macrovascular complications in patients with diagnosis of diabetes mellitus type II. Methods. A cross-sectional descriptive study was carried out in 98 patients diagnosed with diabetes mellitus type II admitted to CIMEQ during the period from January 2015 to December 2016. Results. 58,2 % were females and age groups from 60 to 70 years old were predominant (n=39). In 58 patients the development of diabetes in time was over 20 years old. The chosen treatment was metformin which had a better glycaemic control. The poor glycaemic control was associated to a higher probability of arterial hypertension, a total body and abdominal obesity, and hypertriglyceridemia. A poor glycaemic control was present in 64,3 % and macrovascular complications were present in 70,4 % with a close relation between them (p<0,001). Conclusions. The prevailing poor glycaemic control in patients with diabetes mellitus type II kept a close relation with macrovascular complications and with development in time of over 20 years old from the beginning of the disease.


REFERENCES

  1. Refer Ceballos GR, Ramírez IS, Calzada CC, Olivares IC. Disfunción endotelial y estrés oxidativo. Endocrinol Nutr. 2006; 14:233-6.

  2. Vanhoutte PM. Endothelial control of vasomotor function from health to coronary disease. Circ J. 2008; 67:572-5.

  3. Deanfield J et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005; 23:7-17.

  4. Roque Rodríguez C, Nápoles Magaña R, Escobar Carmona E, Durañones Góngora S. Perfil lipídico y factores de riesgo cardiovascular en pacientes geriátricos. Santiago de Cuba. 2010-2011. Gaceta Méd Espirituana. 2012 [citado 16 Abr 2013]; 14(2). Disponible en: http://bvs.sld.cu/revistas/gme/pub/ vol.14.%282%29_15/p15.html.

  5. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complication experience (1983-2005). Arch Intern Med. 2009; 169(14).

  6. Madonna R, De Caterina R. Aterogénesis y diabetes: resistencia a la insulina e hiperinsulinemia. Rev Esp Cardiol. 2012; 19:234-48.

  7. GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.” Lancet. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442.

  8. Arrieta F, et al. Diabetes mellitus y riesgo cardiovascular: recomendaciones del Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2015). Clin Invest Arterioscl. 2015. http://dx.doi.org/10.1016/j.arteri.2014.12.003DOCUMENTO DE CONSENSO

  9. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes. 2011; 29:116-22.

  10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000; 321:405-23.

  11. García F, Malo F, Modroño M, et al. Diabetes Mellitus tipo 2. 2014. Disponible en: http://www.fisterra.com/guias-clinicas/diabetes-mellitus-tipo-2/

  12. González-Chávez A, Elizondo-Argueta S, Gutiérrez-Reyes G, León-Pedroza JI. Implicaciones fisiopatológicas entre inflamación crónica y el desarrollo de diabetes y obesidad. Cir Cir. 2011; 79:209-16.

  13. Cruz Hernández J, Licea Puig ME, Hernández García P, Yanes Quesada M, Salvato Dueñas A. Disfunción endotelial y diabetes mellitus. Rev Cubana Endocrinol. 2012; 23:166-85.

  14. Hernández JC, Puig MEL, García PH, Marcel EAA, Quesada MY. Estrés oxidativo y diabetes mellitus. www. medigraphic. org. Mx. 2011; 58:4-15.

  15. Pereira Despaigne OL, Palay Despaigne MS, Rodríguez Cascaret A. La diabetes mellitus y las complicaciones cardiovasculares. MediSan. 2015; 19:675-83.

  16. Marisel J, Aquino MF, Aráoz NS, Fernández SV, Gorban SB. Prevalencia de enfermedad coronaria en pacientes con diabetes mellitus tipo II. Revista de Postgrado de la VIa Cátedra de Medicina. 2010; 200:4-9.

  17. López I, Mendoza M, Rodríguez C, Álvarez L. Características Clínicas de pacientes con Diabetes Mellitus 2 del Centro de Salud Familiar "Chiguay". Revista Anacem. 2009; 3(1).

  18. Machado-Alba JE, Moncada-Escobar JC, Gaviria H. Quality and effectiveness of diabetes care for a group of patients in Colombia. Rev Panam Salud Pública. 2009; 26(6): Disponible en: http://www.scielosp.org/scielo.php? script=sci_arttext&pid=S1020-49892009001200008&lng=en.doi:10.1590/ S1020-49892009001200008.

  19. Díaz O, Valenciaga JL, Domínguez E. Características clínicas de la diabetes mellitus tipo 2 en el municipio de Güines. Año 2002. Rev Cubana Endocrinol. 2003; 14(1).

  20. Ewenighi CO, Uchechukwu D, Adejumo BI, Onyeanusi JC, Nnatuanya IN, Onoh OG, et al. Responses to glycemic control therapy according to age, gender, level of adiposity, and duration of diabetes in type 2 diabetic patients. Indian J Med Sci. 2013; 67:61-9.

  21. Twigg SM, Escalada J, Grisoni ML, Stella P, Merino-Trigo A, Lavalle-Gonzalez FJ, et al. Age, BMI, and diabetes duration: effect on glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes (T2DM). 75th Scientific sessions of ADA, Boston, USA, 5–9 June 2015.—2015.—Abstract 1017-P.

  22. McCullough AJ. Epidemiology of the metabolic syndrome in the USA. Journal of digestive diseases. 2011; 12:333-40.

  23. Dìaz E, Orejuela M, Pinza L. Factores relacionados con el control glucémico de pacientes con diabetes mellitus tipo 2 atendidos en tres hospitales de la ciudad de Quito-Ecuador. Rev Med Vozandes. 2012; 23 :5-14.

  24. Franch-Nadal J, Roura-Olmeda P, Benito-Badorrey B, Rodriguez-Poncelas A, Coll-de-Tuero G, Mata-Cases M, & GEDAPS (Primary care Group for the study of Diabetes. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. Family practice. 2015; 32:27-34.

  25. Salazar ÁLvarez Y. Uso de la metformina en la diabetes mellitus tipo II. Revista Cubana de Farmacia. 2011; 45:157-66.

  26. López-Jaramillo P, Sánchez RA, Díaz M, Cobos L, Bryce A, Parra-Carrillo JZ, et al. Consenso latinoamericano de hipertensión en pacientes con diabetes tipo 2 y síndrome glucémico. Acta Med Colomb. 2013; 38:154-72.

  27. Gómez-Huelgas R, Bernal López MR, Villalobos A, Mancera-Romero J, Baca-Osorio AJ, Jansen S, et al. Hypertriglyceridemic waist: an alternative to the metabolic syndrome? Results of the IMAP Study (multidisciplinary intervention in primary care). Int J Obes. 2011; 35:292-9.

  28. Quisiguiña C. Factores que inciden en el incremento de las complicaciones de la Diabetes Mellitus Tipo 2 en el Servicio de Medicina Interna del Hospital Alfredo Noboa Montenegro Cantón Guaranda provincia Bolívar, Periodo Febrero 2009- Febrero 2010. Escuela Superior Politécnica de Chimborazo. Facultad de Salud Pública. Escuela de Medicina. Tesis de Grado. 2010. Disponible en: http://dspace.espoch.edu.ec/bitstream/123456789/1892/1/ 94T00069.pdf

  29. So WY, Raboca J, Sobrepena L, Yoon KH, Deerochanawong C, Ho LT, et al. Comprehensive risk assessments of diabetic patients from seven Asian countries: the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes 2011; 3:109e18.

  30. Guerra M, Lujan D, Alvarado M. Estudio del perfil lipídico en sujetos con Diabetes Mellitus Tipo 2 de Bogotá. Pontificia Universidad Javeriana. Revista de la Facultad de Ciencias. 2015; 10:81-9.

  31. Clair C, Rigotti NA, Porneala B, Fox CS, D’Agostino RB, Pencina MJ, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013; 309:1014-21.

  32. Ohkuma T, Iwase M, Fujii H, Kaizu S, Ide H, Jodai T, et al. Dose-and time-dependent association of smoking and its cessation with glycemic control and insulin resistance in male patients with type 2 diabetes mellitus: the fukuoka diabetes registry. PloS one. 2015; 10(3), e0122023.

  33. Melin EO, Thunander M, Svensson R, Landin-Olsson M, Thulesius HO. Depression, obesity, and smoking were independently associated with inadequate glycemic control in patients with type 1 diabetes. Eur J Endocrinol. 2013; 168:861-9.

  34. Sánchez Maciá M, Castaño Picó MJ. Prevalencia de enfermedad arterial periférica en distintos países. Factores de riesgo y tratamiento. Revista Científica de Enfermería. 2011; 3. Disponible en: http://rua.ua.es/dspace/ handle/10045/44855

  35. Valdés Ramos E, Camps Arjona MDC. Características clínicas y frecuencia de complicaciones crónicas en personas con diabetes mellitus tipo 2 de diagnóstico reciente. Rev Cubana Med Gen Integr. 2013; 29:121-




2020     |     www.medigraphic.com